Silver Book Fact

A year-long study of patients with congestive heart failure found that increased use of medicines increased pharmaceutical costs by 60%; however, hospital costs declined by 78%, producing a net savings of $9.3 million. The ability of patients to perform activities of daily living went up 15% and the death rate dropped from an expected 25% to 10%.

Managed Healthcare. Provide Education About Congestive Heart Failure and Pump Up Your Savings; Mar-1998:42-4

Reference

Title
Provide Education About Congestive Heart Failure and Pump Up Your Savings
Publication Date
Mar-1998
Authors
Managed Healthcare
Volume & Issue
Volume 8, Issue 4
Pages
42-4

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Data from clinical trials demostrate that ICDs reduce sudden cardiac death 5-10% per year for 2-3 years, compared to antiarrhythmic drugs.  
  • Stroke prevention through optimal anticoagulation
    If half of atrial fibrillation patients who currently receive warfarin in a routine care setting had their anti-coagulation optimized, around 9,000 strokes and more than 29,000 bleeds would be prevented.  
  • Cost of warfarin therapy for AFib patients
    In patients with nonvalvular atrial fibrillation (AF) and one additional stroke risk factor, warfarin therapy cost $8,000 per quality-adjusted life-year (QALY) saved.  
  • Every additional dollar spent on the routine use of beta-blockers (versus under-use) in acute heart attack patients has produced health gains valued as high as $38.44.  
  • Development and widespread use of left ventricular assist devices could result in a 50% decrease in heart failure-related hospitalizations.